BIO-
Bio-Rad Laboratories Inc
NYSE: BIO-B · HEALTHCARE · MEDICAL DEVICES
$279.10
-6.80% today
Updated 2026-04-30
Market cap
$8.08B
P/E ratio
10.75
P/S ratio
3.13x
EPS (TTM)
$27.85
Dividend yield
—
52W range
$247 – $321
Volume
0.0M
Bio-Rad Laboratories Inc (BIO-B) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.43B | $1.60B | $1.97B | $2.04B | $2.54B | $3.06B | $3.10B | $3.44B | $3.39B | $3.34B | $3.71B | $3.85B | $4.27B | $5.61B | $8.01B | $12.97B | $17.80B | $13.50B | $12.30B | $9.36B |
| Cash & equivalents | $296.72M | $223.61M | $161.76M | $204.52M | $649.94M | $906.55M | $574.23M | $463.39M | $331.55M | $413.25M | $457.55M | $456.26M | $383.82M | $431.53M | $660.67M | $662.21M | $470.78M | $434.21M | $403.80M | $488.10M |
| Current assets | $1.01B | $1.13B | $1.03B | $1.09B | $1.56B | $1.98B | $1.80B | $1.94B | $1.76B | $1.72B | $1.78B | $1.84B | $1.98B | $2.02B | $2.18B | $2.14B | $1.99B | $3.16B | $3.05B | $3.03B |
| Total liabilities | $768.61M | $776.63M | $999.90M | $966.62M | $1.26B | $1.52B | $1.35B | $1.43B | $1.20B | $1.16B | $1.22B | $1.27B | $1.34B | $1.59B | $2.25B | $3.09B | $4.11B | $3.89B | $3.56B | $2.79B |
| Current liabilities | $319.24M | $319.53M | $414.17M | $418.03M | $419.97M | $666.63M | $459.12M | $472.40M | $487.47M | $446.76M | $441.35M | $471.32M | $502.70M | $450.80M | $905.50M | $631.54M | $680.94M | $568.71M | $522.80M | $467.80M |
| Long-term debt | — | — | — | — | — | — | — | $732.41M | $435.62M | $423.50M | $421.90M | $434.19M | $434.58M | $438.94M | $13.58M | $12.26M | $10.51M | $1.20B | $1.20B | $1.20B |
| Shareholder equity | $657.97M | $819.54M | $971.69M | $1.04B | $1.26B | $1.54B | $1.74B | $2.02B | $2.19B | $2.19B | $2.49B | $2.58B | $2.93B | $4.02B | $5.76B | $9.88B | $13.69B | $9.62B | $8.74B | $6.57B |
| Retained earnings | $570.81M | $674.07M | $762.07M | $851.58M | $996.20M | $1.18B | $1.36B | $1.53B | $1.61B | $1.69B | $1.81B | $1.83B | $1.83B | $3.72B | $5.47B | $9.27B | $13.53B | $9.90B | $9.26B | $7.42B |
| Accounts receivable | $247.19M | $292.97M | $358.08M | $339.65M | $345.73M | $388.00M | $398.67M | $398.74M | $422.66M | $377.64M | $391.49M | $372.35M | $464.85M | $392.44M | $392.67M | $419.42M | $423.54M | $494.64M | $489.00M | $452.50M |
| Inventory | $212.34M | $253.04M | $321.01M | $375.62M | $351.21M | $398.10M | $433.51M | $455.12M | $516.25M | $471.00M | $490.22M | $524.96M | $594.80M | $583.82M | $554.01M | $622.25M | $572.24M | $719.32M | $780.50M | $760.00M |
| Goodwill | — | $119.49M | $328.44M | $321.82M | $327.63M | $363.98M | $468.90M | $495.40M | $517.80M | $500.40M | $495.90M | $477.10M | $506.10M | $219.80M | $264.10M | $291.90M | $347.30M | $406.50M | $413.60M | $410.50M |